Immuneering Corporation

NasdaqGM:IMRX Stock Report

Market Cap: US$71.2m

Immuneering Balance Sheet Health

Financial Health criteria checks 6/6

Immuneering has a total shareholder equity of $90.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $102.6M and $12.0M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$85.67m
EquityUS$90.58m
Total liabilitiesUS$12.01m
Total assetsUS$102.58m

Recent financial health updates

Recent updates

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Immuneering wins FDA nod to study lead asset in solid tumors

Sep 30

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Sep 02

Immuneering initiated a Buy by Chardan, PT set to $18

Jul 08

Financial Position Analysis

Short Term Liabilities: IMRX's short term assets ($89.1M) exceed its short term liabilities ($7.8M).

Long Term Liabilities: IMRX's short term assets ($89.1M) exceed its long term liabilities ($4.2M).


Debt to Equity History and Analysis

Debt Level: IMRX is debt free.

Reducing Debt: IMRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMRX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 36.6% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.